As ubiquitination is a reversible process, the regulation of deubiquitinase activity can be utilized as a new drug design strategy in the treatment of autoimmune diseases caused by excessive activation of the AIM2 inflammasome. The gene discussed is AIM2; the disease is autoimmune disease.